|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-8-13
|
|
pubmed:abstractText |
Sustained virological response (SVR) is the primary objective in the treatment of chronic hepatitis C (CHC). Results from a recent clinical trial of patients with previously untreated CHC demonstrate that the combination of peginterferon alpha-2a and ribavirin produces a greater SVR than interferon alpha-2b and ribavirin combination therapy. However, the cost-effectiveness of peginterferon alpha-2a plus ribavirin in the U.S. setting has not been investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
pubmed-author:BernsteinD EDE,
pubmed-author:CheinquerHH,
pubmed-author:CooksleyGrahamG,
pubmed-author:CraxiAA,
pubmed-author:FosterG RGR,
pubmed-author:GreenJJ,
pubmed-author:HassaneinT ITI,
pubmed-author:JensenD MDM,
pubmed-author:KlaskalaWW,
pubmed-author:LeeS SSS,
pubmed-author:PatelK KKK,
pubmed-author:PettitKK,
pubmed-author:SullivanS DSD
|
|
pubmed:copyrightInfo |
Copyright 2004 American College of Gastroenterology
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1490-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15307866-Antiviral Agents,
pubmed-meshheading:15307866-Cost-Benefit Analysis,
pubmed-meshheading:15307866-Disease Progression,
pubmed-meshheading:15307866-Drug Therapy, Combination,
pubmed-meshheading:15307866-Genotype,
pubmed-meshheading:15307866-Health Care Costs,
pubmed-meshheading:15307866-Hepacivirus,
pubmed-meshheading:15307866-Hepatitis C, Chronic,
pubmed-meshheading:15307866-Humans,
pubmed-meshheading:15307866-Interferon-alpha,
pubmed-meshheading:15307866-Polyethylene Glycols,
pubmed-meshheading:15307866-Quality-Adjusted Life Years,
pubmed-meshheading:15307866-Randomized Controlled Trials as Topic,
pubmed-meshheading:15307866-Recombinant Proteins,
pubmed-meshheading:15307866-Ribavirin,
pubmed-meshheading:15307866-United States,
pubmed-meshheading:15307866-Viral Load
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
|
|
pubmed:affiliation |
University of Washington, Seattle WA 98195, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
